Arcellx (NASDAQ:ACLX) Cut to Hold at Leerink Partners

Leerink Partners downgraded shares of Arcellx (NASDAQ:ACLX) from a strong-buy rating to a hold rating in a report published on Monday,Zacks.com reports.

Several other equities analysts have also issued reports on the company. Stifel Nicolaus reissued a “hold” rating and issued a $115.00 price target (down from $127.00) on shares of Arcellx in a research note on Monday. Robert W. Baird restated a “neutral” rating and set a $115.00 price objective (up from $106.00) on shares of Arcellx in a report on Monday. UBS Group cut shares of Arcellx from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $100.00 to $115.00 in a report on Tuesday. Wolfe Research started coverage on shares of Arcellx in a report on Tuesday, November 18th. They issued a “peer perform” rating on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcellx in a research note on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Arcellx has a consensus rating of “Hold” and an average price target of $111.87.

Arcellx Trading Up 0.0%

Shares of ACLX stock opened at $113.76 on Monday. The stock has a 50-day moving average of $69.82 and a 200-day moving average of $75.65. The stock has a market cap of $6.58 billion, a price-to-earnings ratio of -28.95 and a beta of 0.36. Arcellx has a 1-year low of $47.86 and a 1-year high of $114.26.

Insider Buying and Selling

In other Arcellx news, insider Christopher Heery sold 5,882 shares of the company’s stock in a transaction on Wednesday, January 14th. The stock was sold at an average price of $68.51, for a total value of $402,975.82. Following the completion of the transaction, the insider owned 23,749 shares in the company, valued at $1,627,043.99. This represents a 19.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 19,450 shares of company stock worth $1,283,477 in the last 90 days. Company insiders own 8.35% of the company’s stock.

Institutional Trading of Arcellx

A number of large investors have recently added to or reduced their stakes in the stock. MAI Capital Management bought a new stake in Arcellx in the third quarter worth about $26,000. CWM LLC increased its position in Arcellx by 267.0% in the third quarter. CWM LLC now owns 345 shares of the company’s stock worth $28,000 after buying an additional 251 shares during the last quarter. State of Wyoming purchased a new stake in Arcellx in the second quarter worth $28,000. Ramirez Asset Management Inc. bought a new stake in Arcellx in the 3rd quarter valued at about $41,000. Finally, PNC Financial Services Group Inc. lifted its holdings in Arcellx by 183.4% during the second quarter. PNC Financial Services Group Inc. now owns 751 shares of the company’s stock valued at $49,000 after purchasing an additional 486 shares during the last quarter. Hedge funds and other institutional investors own 96.03% of the company’s stock.

More Arcellx News

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx for up to $7.8 billion, a transformational M&A outcome that explains much of the upward price pressure by crystallizing acquisition value for ACLX shareholders. Gilead to buy Arcellx
• Neutral Sentiment: HC Wainwright published a FY2030 EPS projection (very bullish numerically) with a $115 price target but maintained a “Neutral” rating — the target is close to the current trade and offers limited additional upside. (Source: market research note)
• Neutral Sentiment: Short‑interest data reported for late February shows 0 shares and a 0.0 days‑to‑cover figure, which appears to be a data anomaly and therefore provides no clear signal about short‑seller pressure.
• Negative Sentiment: A broad set of sell‑side shops (Leerink, Evercore, Needham, Wells Fargo, Citigroup, Truist, Canaccord and others) moved ACLX toward “Hold” from stronger stances (strong‑buy/buy/outperform). Several firms cut or trimmed price targets (Truist cut to $120 from $134; others adjusted targets and ratings), creating short‑term headwinds and mixed sell signals despite the M&A news. Citigroup downgrades Arcellx Analyst coverage roundup

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.